<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01994239</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0160/1204</org_study_id>
    <nct_id>NCT01994239</nct_id>
  </id_info>
  <brief_title>Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy</brief_title>
  <acronym>GETUG-AFU22</acronym>
  <official_title>A Multicenter Randomised Phase II Study Comparing the Efficiency of a HT Concomitant With RT vs RT Alone in the Salvage of Patients With a Detectable PSA After Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to select the best therapeutic strategy in studying the
      effectiveness of the association of a short duration hormonal therapy and radiotherapy
      compared with radiotherapy alone, in patients with a detectable PSA after radical
      prostatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study the effectiveness of the association of a short duration hormonal therapy by degarelix
      (Firmagon ®) and radiotherapy, with radiotherapy alone on survival without events in the
      treatment of detectable PSA after radical prostatectomy.

      122 patients should be included over a period of 2 years. Patients will be treated according
      to the following scheme:

        -  Arm A (61 patients) : Pelvic Radiotherapy: 46 Gy and prostate only boost up to 66 Gy

        -  Arm B (61 patients) : Arm A + hormonal therapy by degarelix during 6 months
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of the combination of hormonal therapy by degarelix and radiotherapy on event-free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival without biological event</measure>
    <time_frame>5 years</time_frame>
    <description>Biochemical recurrence was defined as a PSA &gt; nadir + 0.4 ng / mL confirmed by a second PSA&gt; nadir + 0.4 ng / mL in elevation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without clinical event</measure>
    <time_frame>5 years</time_frame>
    <description>The clinical recurrence will be defined by the discovery of a local recurrence in rectal examination, the appearance of metastases by imaging or biopsy, or clinical manifestation associated with malignant disease without elevated PSA but with histological documentation or imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without metastases</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicities of the association of hormone therapy with radiotherapy</measure>
    <time_frame>up to 5 years</time_frame>
    <description>according CTC-AE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities of radiotherapy</measure>
    <time_frame>up to 5 years</time_frame>
    <description>according CTC-AE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>up to 5 years after the end of the radiotherapy</time_frame>
    <description>QLQ-C30, QLQ-PR25 and IPSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kinetics of testosterone</measure>
    <time_frame>up to 12 months after the end of the radiotherapy and after biological release</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Adenocarcinoma of Prostate</condition>
  <arm_group>
    <arm_group_label>Radiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pelvic radiotherapy
46 Gy in 23 fractions of 2 Gy.
prostate only-boost up to 66 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation and Degarelix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy:
46 Gy in 23 fractions of 2 Gy.
prostate only-boost up to 66 Gy
Associated with hormonal therapy by degarelix:
beginning in parallel to radiotherapy for 6 months
First dose of 240 mg
Maintenance dose of 80 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)</description>
    <arm_group_label>Radiation and Degarelix</arm_group_label>
    <other_name>Firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pelvic Radiotherapy</intervention_name>
    <description>46 Gy in 23 fractions Prostate only-boost up to 66 Gy</description>
    <arm_group_label>Radiation</arm_group_label>
    <arm_group_label>Radiation and Degarelix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with localized prostate adenocarcinoma treated with radical prostatectomy
             (whatever the initial prognostic stage)

          2. R0 or R1

          3. pN0 or pNx

          4. Post prostatectomy PSA ≥ 0,2 ng/mL measured between 1 month and 4 months after surgery
             and increasing to a second test performed between 1 et 8 month after the post
             prostatectomy dosage

          5. PSA ≤ 2 ng/mL at moment of the randomisation

          6. No clinical signs of progressive disease (bone scan or PET scan or abdominal and
             pelvic scan or MRI): N0, M0

          7. Neutrophils ≥ 1500/mm3; platelet count ≥ 100 000/mm3

          8. Bilirubin ≤ ULN; ALP, AST et ALT ≤ 1,5 ULN

          9. Creatinine &lt; 140 µmol/L (or clearance &gt; 60mL/min)

         10. Normal fasting glucose

         11. ECOG ≤ 1

         12. Age &gt; 18 years

         13. Life expectancy ≥ 10 years

         14. Patients with invasive cancer in complete response for more than five years are
             eligible

         15. Patients who have received the information sheet and signed the informed consent form

         16. Patients with a public or a private health insurance coverage

        Exclusion Criteria:

          1. Prostate cancer histology other than adenocarcinoma

          2. Patients pN1, N1 and M1

          3. History of pelvic radiotherapy

          4. Contraindication to pelvic irradiation (eg, scleroderma, chronic inflammatory bowel
             disease, etc.).

          5. Testosterone ≤ 0,5 ng/mL

          6. History of surgical castration

          7. Previous treatment by hormonotherapy

          8. Antineoplastic treatment in progress

          9. History of another invasive cancer within 5 years before inclusion (with the exception
             of a basal cell skin carcinoma treated)

         10. Known pituitary adenoma

         11. Severe hypertension uncontrolled by appropriate treatment (160 mm Hg systolic and / or
             90 mm Hg diastolic)

         12. Patient with a corrected QT interval (using Fridericia correction) greater than 450
             msec

         13. Individual deprived of liberty or placed under the authority of a tutor

         14. Unable to undergo medical monitoring test for geographical, social or psychological
             reasons

         15. Known hypersensitivity to the treatment in test

         16. Administration of an investigational therapeutic within 28 days prior to the screening
             visit or more if treatment is likely to influence the outcome of this
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane GUERIF</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Poitiers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Salomon</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Henri Mondor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest -Site Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'oncologie - Clinique Pasteur</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Chambéry</name>
      <address>
        <city>Chambéry</city>
        <zip>73011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'oncologie et de radiothérapie du Parc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte-Marguerite</name>
      <address>
        <city>Hyeres</city>
        <zip>83400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chd Vendee</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Clairval</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Timone - Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Oncorad Garonne Clinique Du Pont de Chaume</name>
      <address>
        <city>Montauban</city>
        <zip>82017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ghi Le Raincy / Montfermeil</name>
      <address>
        <city>Montfermeil</city>
        <zip>93370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Azureen de Cancerologie</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Emile Muller</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06088</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Caremeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Orléans La Source</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées du Val de Grâce</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de POITIERS</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHP Saint Grégoire</name>
      <address>
        <city>Saint Gregoire</city>
        <zip>35760</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Cote Emeraude</name>
      <address>
        <city>Saint Malo</city>
        <zip>35404</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de Radiologie</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste de l'Estuaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie LUCIEN NEUWIRTH</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux du Léman</name>
      <address>
        <city>Thonon-les-Bains</city>
        <zip>74200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Oncorad Garonne</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Marie Curie</name>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GUSTAVE ROUSSY, Cancer Campus, Grand Paris</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.unicancer.fr</url>
    <description>Site UNICANCER</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>May 6, 2018</last_update_submitted>
  <last_update_submitted_qc>May 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate-Specific Antigen</keyword>
  <keyword>LHRH antagonist</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

